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Cathepsin D (CTSD) is a lysosomal protease important for the degradation of various
substrates, including disease-associated proteins like α-synuclein (a-syn), amyloid
precursor protein (APP) and tau, all of which tend to aggregate if not efficiently degraded.
Hence, it is not surprising that genetic variants within the CTSD gene have been
linked to neurodegenerative diseases, like Parkinson’s and Alzheimer’s disease (PD,
AD), as well as the lysosomal storage disorder neuronal ceroid lipofuscinosis type-10
(NCL10). Although recent studies have shown the molecular dependence of substrate
degradation via CTSD within autophagic pathways, only little is known about the
precise role of lysosomal CTSD function in disease development. We here performed
biochemical, cellular and structural analyses of eleven disease-causing CTSD point
mutations found in genomic sequencing data of patients to understand their role
in neurodegeneration. These CTSD variants were analyzed for cellular localization,
maturation and enzymatic activity in overexpression analyses. Moreover, for PD-
associated mutants, intracellular degradation of a-syn was monitored. In summary,
our results suggest that NCL10-associated CTSD variants are significantly impaired
in lysosomal maturation and enzymatic activity, whereas the AD- and PD-associated
variants seemed rather unaffected, indicating normal maturation, and lysosomal
presence. Interestingly, a PD-associated CTSD variant (A239V) exhibited increased
enzymatic activity accompanied by enhanced a-syn degradation. By structural analyses
of this mutant utilizing molecular dynamics simulation (MDS), we identified a structural
change within a loop adjacent to the catalytic center leading to a higher flexibility and
potentially accelerated substrate exchange rates. Our data sheds light onto the role
of CTSD in disease development and helps to understand the structural regulation of
enzymatic function, which could be utilized for targeted CTSD activation. Because of
the degradative function of CTSD, this enzyme is especially interesting for therapeutic
strategies tackling protein aggregates in neurodegenerative disorders.
Keywords: lysosomal degradation, molecular dynamics simulation, Parkinson’s disease, neuronal ceroid
lipofuscinoses, lysosomes, alpha-synuclein, cathepsin D
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INTRODUCTION
The aspartic protease Cathepsin D (CTSD) is involved in
the lysosomal recycling and degradation of many substrates,
including the Parkinson’s disease (PD)-associated protein
α-synuclein (a-syn) (Sevlever et al., 2008). CTSD is ubiquitously
expressed, being particularly abundant in the brain (Stoka et al.,
2016). Several genomic variants of CTSD, like coding missense
mutations, seem to be related to neurodegenerative diseases, such
as neuronal ceroid lipofuscinosis (NCL), Alzheimer’s disease
(AD), and PD, all progressive disorders involving the central
nervous system (CNS) and aggregation of misfolded proteins
(Siintola et al., 2006; Steinfeld et al., 2006; Fritchie et al., 2009;
Hersheson et al., 2014; Robak et al., 2017). Interestingly, the
exact role of CTSD dysfunction in disease progression as well as
its therapeutic potential in neurodegenerative disorders is not
well understood.
Numerous studies highlight the functional role of CTSD
in neurogenesis and neuronal communication (Partanen et al.,
2008; Koch et al., 2011), as well as its pivotal role in lysosomal
proteolysis, since CTSD dysfunction has been shown to lead to
the accumulation of non-degraded substrates in the lysosomes
(Cullen et al., 2009; Bae et al., 2015; Marques et al., 2019). As
lysosomal dysfunction and substrate aggregation is especially
toxic to postmitotic cells, like neurons, it is not surprising
that many lysosomal storage disorders present with neurological
impairments and vice versa, many neurodegenerative diseases
are characterized by lysosomal dysfunction (Klein and Mazzulli,
2018; Wallings et al., 2019; Zunke, 2020). This underlines
the importance of intact lysosomal enzyme function especially
within neuronal cells.
Before CTSD can act as lysosomal protease, it undergoes a
gradual maturation via the secretory pathway, being synthesized
as an inactive precursor pro-enzyme comprising 412 amino acids
(aa). After removal of the N-terminal signal peptide within the
endoplasmic reticulum (ER), the inactive proCTSD (∼52 kDa)
is glycosylated and transported to the Golgi compartment,
where the mannose residues are phosphorylated for targeting
to lysosomes via the mannose-6-phosphate pathway. An acidic
environment is crucial for proteolytic processing and maturation
of CTSD. Once in the endosomes, the phosphate groups and pro-
peptide of 44 aa are removed to generate an active intermediate
(∼48 kDa). In the lysosomal compartment, this single-chain
intermediate is further processed into a double-chain mature
form consisting of an N-terminal light chain (∼14 kDa) and
a C-terminal heavy chain (∼34 kDa), which both remain non-
covalently associated (Zaidi et al., 2008). This highly complex
CTSD processing pathway depicts its vulnerability and potential
effect of CTSD mutations on maturation and enzymatic function.
NCLs are a group of autosomal recessive neurodegenerative
lysosomal storage disorders, and are the most common cause
of pediatric neurodegenerative disease (Vidoni et al., 2016). The
pathological features include the presence of autofluorescent
storage bodies consisting of lipofuscin in lysosomes of neuronal
and glial cells (Koike et al., 2000), resulting in a severe
and progressive loss of motor and psychological abilities
(Mink et al., 2013).
Congenital NCL type-10 (NCL10), the most severe form of the
disease, is caused by mutations within the CTSD gene (Siintola
et al., 2006). Moreover, increasing evidence suggests that CTSD
is also implicated in processing of amyloid precursor protein
(APP) (Zhou et al., 2006) and the tau protein (Ladror et al., 1994;
Kenessey et al., 1997; Vidoni et al., 2016). Both proteins are linked
to AD progression, which is characterized by the extracellular
deposits of the amyloid β-protein (proteolytically processed APP)
and intracellular neurofibrillary tangles of hyperphosphorylated
tau protein (Selkoe, 2001).
Moreover, in vitro and in vivo studies demonstrated that
under physiological conditions, CTSD mediates the lysosomal
proteolysis of a-syn (Sevlever et al., 2008; Cullen et al., 2009;
McGlinchey and Lee, 2015). It was shown that CTSD deficiency
facilitates a-syn-dependent toxicity (Cullen et al., 2009). a-Syn
aggregation is major hallmark of PD, the second most common
neurodegenerative disorder (Kalia and Lang, 2015; Riederer et al.,
2019). Recently, damaging variants of CTSD were found to be
genetically linked to lysosomal dysfunction and PD pathology
in a large screening of PD patients (Robak et al., 2017), further
emphasizing the importance of its lysosomal clearance function
(Klein and Mazzulli, 2018; Zunke, 2020).
In this study, we characterize eleven CTSD variants associated
with neurodegenerative diseases by analyzing their cellular
localization, maturation, enzymatic activity, a-syn degradation
capacity and structural properties. Our findings contribute to a
better understanding of CTSD regulation as well as its role in
disease pathology and a-syn degradation pathways.
MATERIALS AND METHODS
cDNA Constructs and Cloning
Expression plasmids of human (h) CTSD wildtype (wt), the
disease-associated CTSD mutants (A58V, S100F, G149V, F229I,
Y255X, W383C, R399H, V95I, G145V, A239V, and R266H) as
well as the inactive control D97S were cloned via site-directed
mutagenesis PCR utilizing the hCTSD in the pCMV6/pcDNA3.1
vector as a template. All plasmids were verified by DNA
sequencing (GATC Biotech). A plasmid of hα-syn (pcDNA3.1)
was used for co-transfection together with CTSD plasmids for
further analyses of CTSD activity.
Cell Culture
SH-SY5Y neuroblastoma wt and CTSD KO cells were maintained
in advanced Dulbecco’s Modified Eagle’s medium/F12 (DMEM)
(Thermo 611 Fisher Scientific; #12634010) containing 10% heat-
inactivated fetal calf serum (FCS) and 1% penicillin/streptomycin
(Pen/Strep) (PAA Laboratories GmbH; #P11-010). The human
neuroglioma (H4) and the H4 CTSD KO cell line, both expressing
a-syn under the control of a tetracycline inducible promoter
(tet-off system), were cultured in OptiMEM media (Thermo
Fisher Scientific; #31985070) containing 5% FCS, 200 µg/ml
Geneticin (Thermo Fisher Scientific; #10131035) Hygromycin
(Sigma-Aldrich, #H7772-1g), and 1% Pen/Strep.
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iPS Cells Cultivation (2135) and
Differentiation Into Dopaminergic
Neurons
Human induced pluripotent stem (iPS) cell line (2135) from
a healthy control donor was established and characterized
previously (Seibler et al., 2011). iPS cells were maintained
on matrigel (Corning; #354234)-coated dishes with mTeSR1
media (Stemcell Technologies; #85850) and passaged once per
week. iPS cells were differentiated into midbrain dopaminergic
(DA) neurons (iPSn) by using a mixture of growth factors
as described previously (Kriks et al., 2011). In brief, iPS
cell colonies were enzymatically dissociated and seeded onto
matrigel-coated 12 well dishes. When cells reach a confluency
of 80%, the differentiation protocol was initiated by adding
knockout serum replacement (KSR) media with dual SMAD
inhibitors and carried out for 15 days with the addition of
growth and differentiation factors as depicted in detail in
Kriks et al. (2011). Between day 10 and 15, cell layers were
mechanically dissociated into small squares of ca. 2 mm2 and
plated onto a 6-well dish, coated with poly-d-lysine (PDL,
33 µg/mL) and 5 µg/mL laminin. After 25–30 days, the cells
were detached by accutase (Corning; #25-085-Cl), counted, and
plated at a cell number of 4 × 105 cells for western blot
analysis on PDL/laminin-coated 24-well plates. The growth
factors were withdrawn at day 40–50 and cells were aged
until day > 80. iPS-derived DA neurons were maintained in
neurobasal media (Thermo 611 Fisher Scientific, #21103-049)
containing NeuroCult SM1 supplement (Stemcell Technologies,
612 #05711), 1% L-Glutamine (200 mM stock, Gibco; #25030-
081), and 1% Pen/Strep (Sigma-Aldrich; 613 #P0781). The
quality of DA neurons was regularly validated by the presence
of neuronal and midbrain dopamine markers (FOXA2, β-iii-
tubulin, tyrosine hydroxylase and synapsin) by immunostaining
and western blot.
Generation of CTSD Knockout (KO) in
SH-SY5Y and H4 Cells by CRISPR/Cas9
SH-SY5Y neuroblastoma cells and H4 neuroglioma cells were
seeded 2 days before transfection, so that 70–80% confluency
was reached on the day of transfection. Cells were washed
with PBS and were dissociated from the plate by trypsinization
(0.5% Trypsin-EDTA, Gibco, #25300-054). The reaction was
neutralized by adding the 2X volume of normal growth medium.
Cell density was determined by using a cell counter (Nexcelom
Bioscience; #SD100) and cells were transferred to a sterile 1.5 mL
microfuge tube after counting. Each transfection required 50,000
cells. Cells were centrifuged at 500 × g for 5 minutes and
washed again with PBS. After repeated centrifugation, cells were
resuspended in 5 µL resuspension buffer R (Neon Transfection
System 10 µL-Kit; Invitrogen; #MPK1025) per transfection. RNP
(ribonucleoprotein) complexes of CTSD multi RNA guides and
Cas9 protein were assembled as given in the manufacturer’s
protocol (Gene Knockout Kit v2; Synthego; United States). The
multi RNA guides used in this study target the exon 2 of theCTSD
gene. Guide RNA (gRNA) 1: 5′-UAGUUCUUGAGCACCUC-
3′, gRNA 2: 5′-CUCAAAGUACUCCCAGG-3′, and gRNA 3:
5′-ACCAUGUCGGAGGUUGG-3′. 5 µL of cell suspension
was added to each RNP solution. 10 µL of total cell-RNP
solution was filled into a 10 µL Neon tip (Neon Transfection
System 10 µL-Kit; Invitrogen; #MPK1025) and transfected
via electroporation (Neon Transfection System; Invitrogen)
at 1200 V; 20 ms and 3 pulses. Cells were transferred
immediately to a pre-warmed 6-well dish contanining growth
media without antibiotics and incubated until analysis of
mixed pooled CTSD KO cells. Successful editing efficiency was
determined by western blot analysis and Sanger sequencing
of CTSD exon 2. For Sanger sequencing analysis, genomic
DNA was isolated by DNeasy Blood and Tissue Kit from
Qiagen (Qiagen; #69504). Following primers were used to
amplify CTSD exon 2 of pooled CTSD KO cells and
wt cells: forward 5′-GCAGGAGTTTGGTTTTGGCT-3′ and
reverse 5′-ACTCCCAATCACCCTCCCAG-3′. Genomic DNA
was amplified using Q5 High-Fidelity DNA polymerase (New
England Biolabs; # M0491L) by the following PCR protocol:
98◦C for 30 s, 35 cycles of (98◦C for 10 s, 65◦C for 40 s,
72◦C for 30 s), and 72◦C for 5 min. The PCR product was
analyzed by agarose gel electrophoresis using ethidium bromide-
stained 1.5% agarose gel. The PCR product of the correct size
was excised from the gel and DNA was extracted by using
a GeneJET Gel-Extraction Kit (Thermo Scientific; #K0692).
For Sanger sequencing, the following primers were used: 5′-
GCAGGAGTTTGGTTTTGGCT-3′. In order to get single cells,
CTSD KO cells were diluted and seeded at one cell per 96-
well plate. Single CTSD KO cells were grown and expanded
for western blot and Sanger sequencing analysis. The same
procedure was performed to check successful genome editing in
single cell clones.
Transfection and Inhibitor Treatment
In order to ensure reproducibility, the cell count was determined
prior to each transfection by Cellometer R© Auto T4 Plus
(Nexcelom Bioscience; #SD100). SH-SY5Y CTSD KO cells
were seeded into 6-well plates at 2 × 105 cells per well
for western blot analysis and in same density onto 12 mm
cover glasses for immunofluorescence analyses. After 24 h of
expression, cells were transiently transfected with Lipofectamine
2000 (Thermo 611 Fisher Scientific; #11668027) following
the manufacturer’s protocol. Cells were washed in PBS and
harvested for experimental analysis after 48 h and a-syn co-
transfected cells were harvested after 72 h of expression.
H4 CTSD KO cells were plated at a density of 4 × 105
per well (6-well plate) and transfected 24 h later using
Effectene transfection reagent (Qiagen; #301425) according
to the manufacturer’s instructions. H4 CTSD KO cells were
harvested after 48 h of expression. For CTSD inhibition,
pepstatin A (PepA; Sigma-Aldrich; #508437) was diluted in
cell culture media to a final concentration of 100 µM
and incubated for 2 days after transfection. Bafilomycin A1
(BafA1) was used to inhibit the lysosome. BafA1 (Santa
Cruz; #sc-201550A) was dissolved in DMSO and diluted
in cell culture media to a final concentration of 0.2 µM.
Cells were treated with BafA1 one day after transfection
for 16 h.
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Immunofluorescence Analysis
SH-SY5Y CTSD KO cells were fixed in 4% paraformaldehyde
(PFA) for 15 min at 37◦C, permeabilized with 0.3% Triton X-
100 (Roth; #3051.2) in PBS-Triton for 30 min, then blocked
in 2% BSA, 5% heat-inactivated FCS in PBS-Triton (blocking
buffer) for 1 h. The primary antibodies were diluted in
blocking buffer to their working concentration (see below)
and incubated at 4◦C overnight. Cells were washed three
times with PBS-Triton and incubated with secondary antibodies
diluted 1:500 in blocking buffer. Afterwards, cells were washed
three times with PBS-Triton, once with PBS and stained
with DAPI Fluoromount-G (SouthernBiotech; #SBA-0100-20).
Immunofluorescence analyses were performed with a confocal
laser scanning microscope (IX83, Olympus) equipped with a
U Plan S Apo 100X oil immersion objective. Digital images
were processed and analyzed using Inspector Image Acquisition
and Analysis Software (Abberior Instruments). The Pearson’s
correlation coefficient was used to express co-localization of two
stainings. Transfected SH-SY5Y CTSD KO cells were marked
by a region of interest and co-localization of two stainings was
determined with the ImageJ software, resulting in values ranging
from −1 to +1. Positive values describe a positive correlation
between both signals (co-localization), negative values describe
a negative correlation and a value of 0 indicates random
distribution of both signals (Pearson, 1909). Quantification of
LAMP2 was done semiautomatically by thresholding to a similar
intensity for count and length measurement of LAMP2-positive
vesicles in mock and transfected cells.
Primary antibodies used: anti-CTSD (1:100 BD Biosciences;
#610801), anti-LAMP2 (1:250, DSHB, #H4B4). Secondary
antibodies: goat-anti-mouse Alexa Fluor 594 (1:500, Thermo
Fisher Scientific; #A11032) and goat-anti-rabbit Alexa Fluor 488
(1:500, Thermo Fisher Scientific; #A11037).
Western Blot Analysis
All cells were mechanically detached and washed with ice-
cold PBS. SH-SY5Y CTSD KO cell and H4 CTSD KO cell
pellets were extracted in a Triton-based buffer (1% Triton X-
100, 20 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol,
1 mM EDTA, 1.5 mM MgCl2) supplemented with 1 mM
phenylmethanesulfonyl fluoride (PMSF), 50 mM sodium fluoride
(NaF), 2 mM sodium orthovanadate (NaVO3), and a protease
inhibitor cocktail (Roche) by incubation in an ice-water slurry
for 20 min, followed by two freeze and thaw cycles, and
ultracentrifugation at 100,000 × g, 4◦C for 30 min. The soluble
supernatant was then further analyzed. The amount of total
protein was determined by bicinchoninic acid assay (BCA)
(Thermo Fisher; #23227). Samples were denatured with 5 X
Laemmli buffer (0.3 M Tris–HCl, pH 6.8, 10% SDS, 50%
glycerol, 5% β-mercaptoethanol, 5% bromophenol blue) and
heat inactivated at 95◦C for 10 min. Equal amounts of protein
(40 µg) were separated by electrophoresis on a 12% SDS-PAGE
gel and transferred to PVDF-membranes (Merck Millipore;
#IPFL00010). Membranes were blocked in a 1:1 mixture of TBS
and blocking buffer (LI-COR Bioscience; #927-50003) for 1 h. For
a-syn analysis, membranes were fixed in 0.4% PFA for 20 min
before blocking. Primary antibodies were incubated overnight
at 4◦C. Detection was carried out with fluorescence-conjugated
secondary antibodies (LI-COR Biosciences) and detected by an
imaging system (Amersham Typhoon, GE Life Sciences).
Following antibodies were used for detection: anti-CTSD
(1:500; BD Biosciences; #610801), anti-α-syn (Synuclein-1;
1:1000; BD Biosciences; #610787), and anti-GAPDH (1:1,000,
Cell Signaling; #2118).
Cell Lysate CTSD Activity Assay
SH-SY5Y CTSD KO and H4 CTSD KO cells overexpressing
NCL10/AD- and PD-associated CTSD variants were lysed in
a Triton-based buffer (50 mM sodium acetate, 0.1 M NaCl,
1 mM EDTA, 0.2% Triton X-100, pH 4.5) by shaking for 1 h at
4◦C. Lysates were obtained by centrifugation and immediately
used for determination of activity. 2 µl of cell lysates were
incubated in lysis buffer containing 0.1 µM quenched fluorogenic
peptide (Enzo; #BML-P145) and 0.05 mM Leupeptin (Enzo;
#ALX-260-009-M025) at 37◦C for 30 min. Recombinant CTSD
[produced in-house, as recently described (Marques et al., 2019)]
and samples treated with CTSD inhibitor pepstatin A (Sigma-
Aldrich; #P5318-5MG) were used as positive and negative assay
controls, respectively. CTSD activity was measured with an
Infinite R© 200 PRO M Plex multimode microplate reader (ex.:
360 nm; em.: 440 nm; Tecan Trading AG; #TEC006418I). For
every CTSD activity assay, expression of CTSD variants was
verified by western blot. CTSD activity values were normalized
to protein expression level and expressed relative to CTSD wt.
Also, a catalytically inactive CTSD variant was established as
control, replacing one of the aspartic acids (D) comprising
the active site of the enzyme with a serine (S; D97S). This
exchange of a carboxyl group with a hydroxyl group results in an
enzymatically inactive CTSD that still showed normal maturation
and lysosomal localization.
Cell Lysate Cathepsin B (CTSB) Activity
Assay
Cell lysates were produced as described above. 2 µl of the cell
lysates were incubated with 20 µM fluorogenic CTSB substrate
(Z-RR-AMC; Enzo; #BML-P137-0010) diluted in lysis buffer
(50 mM sodium acetate, 0.1 M NaCl, 1 mM EDTA, 0.2%
Triton X-100, pH 4.5) at 37◦C for 30 min. Recombinant CTSB
[produced in-house, as recently described for CTSD (Marques
et al., 2019)] and the addition of the CTSB inhibitor Leupeptin
(Enzo; #ALX-260-009-M025), were used as positive and negative
controls. Detection was performed with an Infinite 200 PRO M
Plex multimode microplate reader (ex.: 360 nm; em.: 440 nm;
Tecan Trading AG; #TEC006418I).
Cell Lysate β-Glucocerebrosidase
(GCase) Activity Assay
Cell lysate extractions were carried out as described above.
Next, 2 µl of the cell lysates were incubated with 1 mM
fluorogenic substrate 4-methylumbellifery-β-D-glucopyranoside
(4MU; Sigma-Aldrich; #M3633) diluted in 4MU buffer (150 mM
citrate/phosphate, 0.25% sodium taurocholate, 0.25% Triton X-
100, pH 5.4) at 37◦C for 1 h. After incubation, equal amounts of
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stop solution (0.4 M Glycerol, pH 10,4) were added to the wells.
Fluorescence signal was measured with an Infinite R© 200 PRO M
Plex multimode microplate reader (ex.: 365 nm; em.: 445 nm;
Tecan Trading AG; #TEC006418I).
Lysosomal Staining
H4 CTSD KO cells (4 × 105 cells) were seeded onto a 6-
well and transfected on the following day (see protocol above).
After 24 h of expression, cells were trypsinized and seeded
onto a 96-well plate (3 × 104 cells per 96 well). The next day,
the cells were treated with 1 mg/ml Dextran, Cascade BlueTM
(Thermo Fisher Scientific; #D1976). The day after, cells were
washed with PBS and the media was replaced by OptiMEM
media without phenol red (Thermo Fisher Scientific; #11520386).
Dextran blue signal, which indicates the lysosomal volume, was
quantified at an excitation wavelength of 400 nm and emission
wavelength of 430 nm. In order to get an accurate normalization
of the Dextran blue signal, normalization to the cell marker
celltag700 (LI-COR; # 926-41090) was performed. For this, cells
were washed in PBS and fixed in 4% PFA for 20 min at RT.
Afterwards, cells were washed again in PBS, permeabilized in
0.3% Trition X-100 in PBS and blocked in blocking buffer
(see section “Immunofluorescence Analysis”). Next, celltag700
was added at a dilution of 1:500 in blocking buffer for 1 h at
RT. The plate was then washed three times in 0.1% Tween20
in PBS. The last wash was conducted in PBS and celltag700
signal was detected by an imaging system (Amersham Typhoon;
GE Life Sciences).
Structural Analysis
As a template for structural analysis, the available structure of a
CTSD dimer with inhibitor 2-(3,4-dimethoxyphenyl)-N-[N-(4-
methylbenzyl)carbamimidoyl]acetamide was used (PDB: 4OBZ).
For the model, only one CTSD molecule was used and the
inhibitor was removed. Moreover, the light chain was colored
light blue and the heavy chain was colored gray. The active
site was highlighted red. Mutated amino acids were marked in
different colors.
Molecular dynamics simulation (MDS) was performed as
described before (Schneppenheim et al., 2017). In short, after
removal of the inhibitor from the CTSD wt structure (PDB:
4OBZ), UCSF Chimera (Pettersen et al., 2004) was used to
exchange alanine 239 to a valine (swapaa) and produce the
A239V-CTSD. VMD (Humphrey et al., 1996) was used to prepare
the structure for MDS in NAMD (Phillips et al., 2005). This
preparation in VMD included the addition of a water box
and the addition of NaCl-ions to neutralize the system. After
100,000 steps of minimization, 1,000,000 steps of simulation
were calculated in NAMD. For CTSD wt and CTSD A239V,
three independent approaches were calculated to assess structural
differences between wt- and A239V-CTSD. All imaging was
performed in UCSF Chimera.
Data Analysis and Statistics
All values are expressed as mean ± SEM. For data analyses,
Excel (Microsoft, Seattle, WA, United States) and GraphPad
Prism version 7 (GraphPad Software for Mac, San Diego, CA,
United States) were used. Differences among mean values were
analyzed by one-way ANOVA, followed by a Tukey’s multiple
comparison test. In all analyses, the null hypothesis was rejected
at p< 0.05 with ∗ <0.05, ∗∗ <0.01, ∗∗∗ <0.001, ∗∗∗∗ <0.0001.
RESULTS
To gain a better understanding of the role of CTSD in disease
development, eleven CTSD point mutations found by genome
sequencing analyses of NCL10, AD or PD patients were analyzed
in overexpression studies by structural and functional readouts.
In order to examine CTSD variants in neural-like cells, a
CTSD knockout (KO) was established in human neuroblastoma
(SH-SY5Y) and neuroglioma (H4) cell lines by CRISPR/Cas9
technology (Supplementary Figures 1A,B). Both cell lines are
frequently used to study neurodegenerative disease pathways.
Interestingly, SH-SY5Y and H4 cells exhibit much higher levels
of endogenous CTSD in comparison to human embryonic kidney
cells (HEK293T), but similar CTSD level as found within human
dopaminergic (DA) neurons derived from induced pluripotent
stem cells (iPSn) (Supplementary Figure 1B). CTSD protein
level and cellular localization was similar and not significantly
altered after overexpression in CTSD-deficient SH-SY5Y cells
(CTSD KO) in comparison to endogenous CTSD within SH-
SY5Y wt cells (Supplementary Figure 1C).
NCL-Associated CTSD Variants Show
Impaired Protein Maturation and
Enzymatic Activity
Mutations within the CTSD gene have been linked to the
severe neuropathic lysosomal storage disorder NCL10 (Siintola
et al., 2006; Steinfeld et al., 2006; Fritchie et al., 2009; Doccini
et al., 2016). For instance, a complete loss of CTSD function
causes an early death of newborns, emphasizing the vital role
of CTSD function (Siintola et al., 2006). A point mutation
within the CTSD gene was also linked to the neurodegenerative
disorder AD (Riemenschneider et al., 2006; Ehling et al., 2013).
Interestingly, the course and severity of disease varies between
the different genetic variants. To learn more about the effect of
each CTSD point mutation, we characterized six NCL10- and
one AD-linked CTSD mutation under the same experimental
conditions by overexpression analyses (Figures 1A,B). The AD-
associated CTSD mutant A58V is the only mutant found in
the pro-peptide of CTSD (Figure 1A, pink), which gets cleaved
during maturation and is not found within the mature protein.
NCL-linked CTSD mutations are found within the light chain
[S100F (yellow), G149V (orange)] and heavy chain [F229I
(cyan), Y255X (green), W383 (blue), R399H (purple)] of the
mature enzyme (Figures 1A,B). The structural representation
of CTSD illustrates the localization of the S100F mutation in
close proximity to the active site amino acid D97 (Figure 1B).
In general, amino acid orientation of all here analyzed CTSD
mutations are facing towards the inside of the protein, which
might explain destabilizing effects on the protein (Figure 1B). For
further analyses, a catalytically inactive CTSD mutant (D97S) was
included as a control.
NCL10- and AD-associated CTSD variants were
overexpressed in SH-SY5Y cells deficient for CTSD (CTSD
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 February 2021 | Volume 9 | Article 581805
fcell-09-581805 February 5, 2021 Time: 16:58 # 6
Bunk et al. Analysis of CTSD Variants
FIGURE 1 | Characterization of CTSD variants associated with neurodegenerative diseases in SH-SY5Y CTSD KO cells. (A) Schematic overview of NCL- and
AD-associated CTSD variants analyzed in this study. During protein maturation, the signal peptide (20 aa) and the propeptide (44 aa) are removed, generating an
intermediate form (∼48 kDa) that is further processed in the lysosome into a double-chain mature form comprised of a light chain (∼14 kDa) and a heavy chain
(∼34 kDa; symbolized by scissor symbol). Both chains remain associated by hydrophobic interactions. Point mutations found in NCL- and AD- patients located
within different protein parts are shown in different colors (A58V, pink, propeptide; S100F, yellow, light chain; G149V, orange, light chain; F229I, light blue, heavy
chain; Y255X, green, heavy chain; W383C, dark blue, heavy chain; R399H, purple, heavy chain). Aspartates D97 and D295 as part the catalytic site are highlighted
in red. (B) Crystal structure model of mature CTSD consisting of the light chain (blue) and the heavy chain (gray) [PDB-ID: 4OBZ (Gradler et al., 2014)]. The active
site, consisting of the two aspartates D97 and D295, is shown in red. Other colors indicate disease-associated point mutations within the CTSD protein (same color
code as in A). (C) Representative immunoblot of transiently overexpressed CTSD wildtype (wt) and NCL-/AD-associated CTSD variants, as well as enzymatically
inactive control (D97S) in SH-SY5Y CTSD KO cells. An anti-CTSD antibody was used for the detection of immature (pro- and intermediate form) as well as mature
(Continued)
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FIGURE 1 | Continued
CTSD (heavy chain, 34 kDa). GAPDH and coomassie brilliant blue (CBB) were used as a loading control. (D) Quantification of western blot signal intensity of mature
CTSD (heavy chain) normalized to GAPDH and expressed relative to CTSD wt (n = 4). (E) Analysis of CTSD activity assessed in whole cell lysates utilizing a
fluorogenic CTSD peptide cleavage assay. The activity was normalized to CTSD wt (n = 4). (F) Representative immunofluorescence pictures of SH-SY5Y CTSD KO
cells expressing CTSD wt or NCL-/AD-associated variants. Cells were visualized by staining of CTSD (green), the lysosomal associated membrane protein LAMP2
(red), and DAPI as nuclear staining (blue). Scale bar: 20 µm. Confocal images showing the single channels can be found in Supplementary Figure 2. All statistical
analyses were performed using a one-way ANOVA followed by a Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ****p < 0.0001, n.s., not significant in
comparison to wt.
KO) and immunoblot analyses were performed to analyze
protein expression, stability as well as CTSD maturation: pro-
(∼52 kDa) and intermediate form (∼48 kDa) were analyzed
together as immature CTSD (Figure 1C). CTSD wt-transfected
cells expressed the mature form of CTSD as depicted by the
presence of the heavy chain (∼34 kDa) (Figure 1C). Only the
AD-variant A58V, S100F and the inactive CTSD control (D97S)
showed similar levels of the heavy chain compared to CTSD
wt (Figures 1C,D). All other NCL-associated CTSD variants
exhibited a significant reduction (F229I) or complete absence
of mature CTSD (G149V, Y255X, W383C, R399H), indicating
impaired protein maturation (Figures 1C,D). Next, the effects
of the NCL- and AD-associated point mutations on enzymatic
CTSD activity were assessed by a fluorogenic peptide cleavage
assay of cell lysates (Figure 1E). All NCL-associated CTSD
variants showed a significantly reduced enzymatic activity in
comparison to CTSD wt, similar to the inactive CTSD control
D97S (Figure 1E). In contrast, CSTD A58V exhibited similar
enzymatic activity as the CTSD wt (Figure 1E).
Since lysosomal localization is crucial for CTSD maturation
as well as for enzyme function, immunofluorescence studies
were performed to analyze cellular localization of CTSD
mutants. SH-SY5Y CTSD KO cells were transfected with
respective CTSD variants and co-stained for CTSD (green) and
lysosomal-associated membrane protein type 2 (LAMP2; red)
as lysosomal marker (Figure 1F and Supplementary Figure 2).
Co-localization and hence lysosomal localization of the CTSD
variants was indicated by overlapping signals (yellow) (Figure 1F
and Supplementary Figure 2). Calculating the co-localization
of CTSD and LAMP2 via the Pearson’s correlation coefficient
revealed no changes in lysosomal localization for CTSD A58V,
S100F, and inactive D97S control (Supplementary Figure 3A).
Confirming the immunoblot (Figures 1C,D), significantly
reduced lysosomal localization was found for all NCL10-
associated CTSD variants with the exception of CTSD S100F,
indicating unimpaired maturation, and lysosomal localization
(Figure 1F). Still, there was no enzymatic activity measured
for the CTSD variant S100F (Figure 1E). Interestingly, the
number of LAMP-2 positive vesicle was increased for the S100F
mutant in comparison to the CTSD wt, whereas all other
CTSD variants did not show any change in vesicle number
(Supplementary Figure 3B). The average size of LAMP2 positive
vesicles was increased for all CTSD variants located within the
heavy chain of the CTSD protein (F291I, Y255X, W383C, R399H)
in comparison to the wt (Supplementary Figure 3C).
Taken together, our results suggest that the AD-associated
variant A58V follows a regular CTSD maturation and is
enzymatically active, whereas all NCL10-associated variants
exhibited impairments of either CTSD maturation and/or
enzymatic function. Moreover, increased size of LAMP2-positive
vesicles for the majority of NCL-associated CTSD variants
indicates severe effects on lysosomal function.
PD-Associated CTSD Variants Follow
Unimpaired Protein Maturation and
Enzymatic Activity
A recent whole exome sequencing analysis in 1156 PD cases and
1670 control subjects discovered four coding point mutations
within the CTSD gene in PD patients (Robak et al., 2017). We
here examined cellular and biochemical characteristics of those
CTSD variants, found in the light chain (V95I, G145V) and heavy
chain (A239V, R266H) of the mature enzyme (Figures 2A,B).
As CTSD is highly expressed in neuronal cell lines
(Supplementary Figure 1B), where it degrades disease-
associated substrates like a-syn and APP (Zhou et al., 2006;
Sevlever et al., 2008; Cullen et al., 2009), we analyzed PD-
associated CTSD variants in SH-SY5Y (Figure 2) as well as H4
cells (Figure 3) deficient for CTSD (CTSD KO). In SH-SY5Y
CTSD KO, no significant difference in protein maturation was
observed for the PD-associated CTSD variants in western blot
analysis in comparison to wt, although mature protein level
were less for the A239V CTSD variant (Figures 2C,D). Next,
enzymatic activity of PD-associated CTSD variants was examined
and no functional impairment could be detected (Figure 2E).
Surprisingly, the CTSD A239V variant showed a 2.5-fold
increased activity compared to CTSD wt (Figure 2E). In line
with the western blot analyses (Figure 2C), immunofluorescence
studies showed lysosomal localization of all PD-associated
CTSD variants as indicated by co-localization with lysosomal
marker LAMP2 (Figure 2F and Supplementary Figure 4), also
confirmed by Pearson’s correlation analysis assessing overlay
of LAMP2 and CTSD signal (Supplementary Figure 5A).
Moreover, there was no change in number or average size
of LAMP2-positive vesicles between wt and CTSD variants
(Supplementary Figures 5B,C).
Overexpression of CTSD PD-mutants in H4 CTSD KO
cells exhibited similar expression and maturation patterns as
observed in SH-SY5Y CSTD KO cells (Figure 3A). However,
in this cell line, the A239V variant showed a significant
reduction of mature protein in comparison to the CTSD wt
(Figures 3A,B). Yet, mature CTSD protein normalized to
immature CTSD level did not exhibit any differences within
PD-associated CTSD variants in both cell lines (SH-SY5Y
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FIGURE 2 | Structural and functional analyses of PD-associated CTSD variants in SH-SY5Y CTSD KO cells. (A) Schematic overview of the CTSD protein (412 aa)
and its maturation intermediates (pro- and intermediate form, together referred to as immature form). Mature CTSD consists of a light chain (∼14 kDa) harboring two
of the total four analyzed PD-associated mutations (V95I and G145V) and the heavy chain containing the A239V and R266H mutation. The aspartates D97 and
D295 of the active site are shown in red. (B) Crystal structure model of mature CTSD protein consisting of the light chain (blue) and the heavy chain (gray) [PDB-ID:
4OBZ (Gradler et al., 2014)]. Active site residues (D97, D295) are shown in red. Other colors indicate PD associated point mutations (V95, black, light chain; G145,
orange, light chain; R266, green, heavy chain; A239, purple, heavy chain). (C) Representative immunoblot of transiently overexpressed CTSD wildtype (wt),
enzymatically inactive control (D97S), and PD-associated CTSD variants in SH-SY5Y CTSD KO cells. An anti-CTSD antibody was used for the detection of immature
(pro- and intermediate form) as well as mature CTSD (heavy chain, 34 kDa). GAPDH and CBB were used as loading control. (D) Quantification of mature CTSD
western blot signal intensity of CTSD variants normalized to loading control GAPDH and expressed relative to CTSD wt (n = 4). (E) CTSD activity was assessed in
whole cell lysates by fluorogenic peptide cleavage assays and normalized to CTSD wt (n = 7). (F) Immunostaining analysis of CTSD (green) and lysosomal protein
LAMP2 (red) in SH-SY5Y CTSD KO cells overexpressing CTSD wt or PD-associated variants. Nuclei are stained with DAPI (blue). Scale bar: 20 µm. More confocal
images also showing single channels can be found in Supplementary Figure 4. All statistical analyses were performed by using a one-way ANOVA followed by a
Tukey’s multiple comparison test. *p < 0.05, ***p < 0.001; n.s., not significant.
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FIGURE 3 | Cellular and functional analyses of PD-associated CTSD variants in H4 CTSD KO cells. (A) Representative immunoblot of CTSD wt, PD-associated
CTSD variants (V95I, G145V, A239V, and R266H) and catalytically inactive mutant D97S overexpressed in neural-like H4 cells deficient for CTSD (CTSD KO). GAPDH
and CBB were used as a loading control. (B) Analysis of CTSD protein expression by quantification of signal intensities of mature CTSD protein bands normalized to
loading control (GAPDH) and expressed relative to CTSD wt (n = 4). (C) CTSD activity assay measured within H4 CTSD KO cell extracts and normalized to CTSD wt
(n = 4). (D) Cathepsin B activity measured in whole cell lysates by fluorogenic peptide cleavage assays and normalized to CTSD wt (n = 3). (E) β-Glucocerebrosidase
(GCase) activity measured in whole cell lysates and normalized to CTSD wt (n = 3). (F) Lysosomal homeostasis was assessed by measuring lysosomal mass using
dextran blue (DexBlue) in a plate reader approach normalized to the cell marker celltag700. The values are shown as ratio to CTSD wt (n = 4). All statistical analyses
were performed by using a one-way ANOVA followed by a Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ****p < 0.0001.
CTSD KO and H4 CTSD KO; Supplementary Figures 5D,E).
This suggests unimpaired maturation of all PD-CTSD variants.
In line with the results in SH-SY5Y CTSD KO cells, a
significant increase (2-fold) in enzyme activity was also
measured in H4 CTSD KO cells transfected with the A239V
mutant (Figure 3C).
To analyze possible cellular effects of CTSD variants on
general cell and lysosomal homeostasis, activity of two other
lysosomal enzymes, comprising cathepsin B (CTSB), and
β-glucocerebrosidase (GCase) were measured in cell lysates. For
CTSB, only the inactive CTSD D97S variant showed a significant
reduction in CTSB activity in comparison to the wt (Figure 3D).
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Also, the GCase activity assay revealed no differences for PD-
associated CTSD variants (Figure 3E). Lysosomal mass as marker
for lysosomal dysfunction was determined by Dextran blue
staining in a live cell plate reader assay, exhibiting no differences
between the different CTSD variants (Figure 3F).
Collectively, these findings demonstrate that protein
maturation, lysosomal localization, as well as enzymatic activity
are not significantly impaired in PD-associated CTSD variants
in SH-SY5Y CTSD KO and H4 CTSD KO cells. Moreover, no
impairment in other lysosomal enzyme function and lysosomal
homeostasis was observed in the H4 CTSD KO cell system
after overexpression of any CTSD variant (wt, PD-associated
or inactive control). Remarkably, CTSD variant A239V leads to
an enhanced activity, suggesting a structural change within the
protein, which will be analyzed in more detail in the following.
PD-Associated CTSD A239V Shows
Enhanced α-Synuclein Degradation
Since a-syn aggregation is a major hallmark of PD, and since
CTSD is responsible for a-syn degradation within lysosomes,
a-syn degradation properties of PD-linked CTSD variants
were analyzed. Within SH-SY5Y CTSD KO cells, the effect
of PD-CTSD variants on a-syn was studied after 72 h of
overexpression by immunoblot analyses (Figure 4A; whole
a-syn western blot: Supplementary Figure 6A). Remarkably,
the CTSD variant A239V was able to decrease a-syn to a
significantly higher degree compared to the CTSD wt (∼25%
less a-syn; Figure 4B). Since all CTSD variants revealed similiar
expression level as exhibted in the western blot (Figure 4A),
this indicates that the point mutation A239V results in an
enhanced a-syn proteolysis, being in line with higher enzymatic
activity measured in SH-SY5Y CTSD KO and H4 CTSD KO
cell lysates for this mutant (Figures 2E, 3C). Moreover, a-syn
level increased after lysosomal (Bafilomycin A1) or CTSD
(pepstatin A) inhibition in SH-SY5Y cells expressing CTSD wt
(Supplementary Figure 6B). This indicates a crucial role of
CTSD in a-syn homeostasis.
Structural Analysis of CTSD A239V
Variant
To gain structural insight into a possible mechanism responsible
for this gain of activity of the CTSD A239V variant, molecular
dynamics simulation (MDS) was applied. For this, the crystal
structure of CTSD bound to the 2S4 inhibitor was used
(Supplementary Figure 7A; PDB-ID: 4OBZ). As a start model
for MDS, the inhibitor was removed (Supplementary Figure 7B)
and alanine 239 was exchanged to a valine (UCSF Chimera;
swapaa). Both, CTSD wt and CTSD A239V were simulated
three times and largest movements were detected for two
helices (indicated by arrows) that closed into the cavity formerly
occupied by the inhibitor (Figures 4C,D). This movement was
detected for both variants. Comparison of the three structures
post-MDS revealed very little movement for CTSD wt in the
loop carrying alanine 239 (filled black arrow) or the adjacent
loop formed by amino acids 75–77 from the light chain (empty
black arrow; Figure 4C). This was different for the A239V variant.
Here, a larger deviation between the three resulting post-MDS
structures was found (Figure 4D). A direct comparison of both
variants from two different directions illustrates this difference
in variability (Supplementary Figures 7E,F). Thus, insertion of
valine at position 239 seems to destabilize not only the loop
carrying the amino acid exchange itself, but also the neighboring
loop formed by amino acids 75–77. This additional instability
might also induce a higher flexibility and thereby accelerate
substrate exchange rates.
Overall, we found strong impairments in the enzymatic
function of NCL-associated CTSD variants, but not in AD- and
PD-linked mutants. These functional differences are surprising
since mutations occur in the same gene and in a linear overview
of the CTSD protein, NCL-/AD- and PD-mutations are found
in close proximity (Figure 5A). Two regions within the light
and heavy chain of the mature CTSD appear to be frequently
affected by mutations: aa 95 – aa 149 (V95I, S100F, G145V,
and G149V) and aa 229 – aa 266 (F229I, A239V, Y255X and
R266H). This could indicate that both regions are crucial for
proper CTSD function. As summarized in Figure 5B, NCL10-
associated CTSD variants G149V, F229I, Y255X, W383C and
R399H (all gray) do not mature, are less active and are not
localized in the lysosome. Interestingly, the S100F mutant
showed unimpaired maturation and lysosomal localization but
no catalytic activity. The AD-associated variant A58V and PD-
associated variants V95I, G145V, A239V, and R266H reach the
lysosome and are enzymatically active. Surprisingly, the A239V
mutant exhibited increased enzymatic activity, that also led to a
higher a-syn turnover compared to the wt, as well as the other
CTSD variants. By further analyzing this mutation, the structural
properties of CTSD activation and substrate turnover can now
be studied, helping in the design of therapeutic approaches
targeting CTSD function.
DISCUSSION
To date, numerous studies emphasize the link between lysosomal
dysfunction and neurodegenerative diseases (Nixon, 2013;
Fraldi et al., 2016; Klein and Mazzulli, 2018; Zunke, 2020).
The efficient degradation of lysosomal substrates (proteins,
lipids, carbohydrates, etc.) is essential for neuronal survival.
The aspartic protease CTSD is a major component of the
lysosome and malfunction of the enzyme has been associated
with severe neurodegenerative disorders, like the neuronal
ceroid lipofuscinosis type 10 (NCL10), but also AD and PD
(Vidoni et al., 2016).
In this study, we show that NCL10- and AD/PD-associated
CTSD point mutants behaved completely different in comparable
overexpression analyses. Whereas all NCL10-CTSD variants
lack maturation and/or enzymatic activity, AD/PD-associated
CTSD variants did not show major impairments in our
experimental set-up. Corresponding to our immunofluorescence
analysis, we speculate that NCL10-CTSD variants (except
S100F) accumulate within the secretory pathway and do not
reach lysosomal structures. The resulting absence of lysosomal
CTSD corresponds to the severe pathology found in NCL10
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FIGURE 4 | Functional and structural impact of PD-associated CTSD A239V mutation. (A) Immunoblot of CTSD variants co-expressed with a-syn in SH-SY5Y
CTSD KO cells. Synuclein-1 (Syn-1) was used for a-syn detection and GAPDH and CBB as loading control. The corresponding whole a-syn western blot can be
found in Supplementary Figure 6A. (B) Quantification of a-syn signal intensity after normalization to loading control, shown relative to CTSD wt (n = 4–7). Statistical
analysis was performed using a one-way ANOVA followed by a Tukey’s multiple comparison test. Significances were tested against CTSD wt (*p < 0.05).
(C) Superimposed image of three CTSD wt structures post MDS. The active site residues are shown in red (spacefill) and amino acid A239 is shown in cyan (ball and
stick). The loop carrying A239 is marked with a black arrow (filled) and the neighboring loop formed by amino acids 75–77 is marked with an arrow (black unfilled).
(D) Superimposed image of three A239-CTSD structures post-MDS. Coloring and annotation with arrows as in (C). Note the stronger deviation of the two loops
when comparing to CTSD wt.
patients (Siintola et al., 2006; Steinfeld et al., 2006; Fritchie
et al., 2009; Hersheson et al., 2014; Kohlschutter et al., 2019;
Regensburger et al., 2020). This course of disease is also partly
recapitulated by the progressive phenotype of a CTSD-deficient
mouse model, that dies prematurely at day 26 ± 1 (Saftig et al.,
1995; Cullen et al., 2009; Marques et al., 2019).
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FIGURE 5 | Summary figure of all in this study investigated disease-associated CTSD variants. (A) Schematic overview of localization of disease-associated CTSD
variants. AD- and NCL-associated CTSD point mutation are shown in gray and PD-associated CTSD variants highlighted in red. Active site residues D97 and D295
are also depicted in gray. (B) Summary table of functional analyses of CTSD variants analyzed in this study. The CTSD wt is shown as reference and + and – symbols
indicate deviation of each CSTD variant from the characteristic/behavior of CTSD wt within individual analyses: (1) maturation of enzyme (immunoblot analysis), (2)
lysosomal localization (immunofluorescence analyses), (3) enzymatic activity (fluorogenic peptide cleavage assay), (4) a-syn degradation (overexpression and
immunoblot analysis). The catalytically inactive CTSD variant (D97S) shows normal maturation and lysosomal localization, but no enzymatic activity. NCL- and
AD-associated CTSD point mutations were not analyzed for a-syn degradation.
In earlier studies, NCL10 patients were clinically examined
and patient’s fibroblasts analyzed for CTSD maturation and
activity. In Steinfeld et al. (2006), a compound heterozygous
patient, carrying the biallelic missense mutations p.F229I
(c.685T > A) and p.W383C (c.1149G > C), was reported
with early blindness and progressive psychomotor retardation.
Analysis of patient’s fibroblasts revealed less mature CTSD and
a significant loss of enzymatic activity. Moreover, analyses of the
individual point mutations in overexpression studies exhibited
a significant decrease in mature CTSD in comparison to the
wt for the F229I variant and absence of mature CTSD for
the W383C variant (Steinfeld et al., 2006). This, together with
a significant reduction of both CTSD variants in enzymatic
activity, is in line with our data. Also, CTSD activity in
fibroblasts of patients expressing the CTSD G149V as well
as the R399H variant was found to be significantly reduced
(Hersheson et al., 2014). Patients carrying the homozygous
missense mutations p.G149V and p.R399H presented with ataxia,
cognitive decline and retinitis pigmentosa at an age of 15 and
8 years, respectively (Hersheson et al., 2014). The homozygous
mutations p.S100F (c.299C > T) and p.T255X (c.764dupA)
resulted in premature death after 2 and 1 days after birth
(Siintola et al., 2006; Fritchie et al., 2009). Interestingly, the
CTSD S100F variant exhibited only marginal CTSD activity in
patient fibroblasts, but the mature protein seemed to be stable in
overexpression studies (Fritchie et al., 2009), which could both
be confirmed in our study. Taken together, all here analyzed
NCL10-CTSD variants show impaired CTSD maturation and/or
enzymatic function, corresponding to the severe symptoms
found in patients.
In contrast, the AD-associated A58V variant reached the
lysosome and showed similar level of mature enzyme as well as
comparable activity to the CTSD wt. In difference to all other
here analyzed CTSD mutants, the A58V variant is located within
the pro-peptide (A58V), which gets cleaved during maturation
and is not present within the mature enzyme. This might
explain why this CTSD variant does not show any cellular or
functional impairments. In patients, CTSD A58V has been found
to be associated with general intelligence in healthy older people
(Payton et al., 2003). Moreover, AD patients expressing this
CTSD mutation showed higher levels of amyloid β-protein as
well as tau protein in the brain (Papassotiropoulos et al., 2002;
Davidson et al., 2006; Riemenschneider et al., 2006). However,
there is still controversy about the association and significant
correlation between the expression of the A58V variant and
the risk of developing AD [pro: (Papassotiropoulos et al., 2000;
Mariani et al., 2006; Albayrak et al., 2010; Schuur et al., 2011;
Sayad et al., 2014); contra: (Bagnoli et al., 2002; Mateo et al., 2002;
Li et al., 2004; Mo et al., 2014)]. Nonetheless, CTSD has been
discussed as therapeutic target in AD (Di Domenico et al., 2016).
Whereas clinical characterization of patients carrying NCL-
/AD-associated CTSD mutations are available (Riemenschneider
et al., 2006; Siintola et al., 2006; Steinfeld et al., 2006; Fritchie
et al., 2009; Ehling et al., 2013; Hersheson et al., 2014), there is no
clinical data on the here analyzed PD-associated CTSD variants,
as they were found in a large genetic-meta analysis (Robak et al.,
2017). PD is characterized by a-syn aggregation within the CNS.
In vitro and in vivo mouse studies demonstrated that proteolysis
of a-syn is mediated by the lysosomal protease CTSD (Sevlever
et al., 2008) and vice versa, the loss of function of CTSD facilitates
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a-syn toxicity (Cullen et al., 2009). However, it is still not well-
understood to what extend CTSD is involved in a-syn turnover
in human neurons. Interestingly, it was shown recently that a-syn
aggregates faster, creating a more toxic form under lysosomal
pH conditions (Eymsh et al., 2020). This points to a critical
role of CTSD in decreasing a-syn level within lysosomes by its
degradative function.
In our study, the four PD-associated CTSD variants resulted
in a similar maturation pattern and were correctly targeted to the
lysosome, similar to CTSD wt in two different cell lines. Testing
for a-syn degradation, we co-transfected cells with a-syn and
the respective CTSD mutants. To our surprise, the proteolytic
capacity of CTSD mutant A239V was enhanced ∼2.0 – 2.5-
fold, which resulted in a more efficient clearance of the a-syn
protein in comparison to the wt (∼25% less a-syn). For structural
analyses, we utilized MDS and found structural changes within
two loop regions that might be responsible for the increase in
activity found in CTSD A239V. The higher flexibility of this
region was deduced from the different conformations received
after MDS. Enzyme activity is always balanced between flexibility
to interact with the substrate and rigidity to ensure stability
of the enzyme (Shoichet et al., 1995). For NADH oxidase of
Thermus thermophilus with a temperature optimum around
70◦C, induction of flexibility can also be achieved by the addition
of 1.0–1.3 M urea at ambient temperature (Zoldak et al., 2003).
In our case, the insertion of a slightly larger amino acid (alanine
to valine) might induce this bit of flexibility, that accounts
for the increase in activity. Interestingly, this mutation was
expressed to a reduced extent than other here analyzed disease-
associated CTSD variants. The increased flexibility of the loop
might also result in a less stable protein that is more prone to
degradation. To further validate the role of the two loops within
the CTSD protein, additional experiments using recombinant
enzyme have to be carried out. Nonetheless, this opens novel
possibilities for treatment strategies targeting protein aggregation
in neurodegenerative disorders. Hence, the use of recombinant
CTSD as therapeutic approach has been shown by an enzyme
replacement approach within a mouse model lacking CTSD.
Marques et al. (2019) provide evidence that the treatment with
recombinant CTSD corrects defective proteolysis and autophagy
in a murine NCL10 model.
Nevertheless, the question about the role and impact of CTSD
mutations on the pathology of neurodegenerative diseases is still
elusive. Since AD- and PD-associated CTSD variants did not
exhibit major impairments in maturation and enzymatic activity
in our overexpression analyses, it could be the case that our
experimental set-up is not sensitive enough to pick up small
functional changes. Since AD and PD usually present at higher
ages, post-mitotic neuronal cells might enrich small amounts
of accumulating substrates over time until reaching critical
concentrations causing neurotoxicity, neuronal cell death and
pathology (Hara et al., 2006; Komatsu et al., 2006). Moreover, it is
possible that other lysosomal cathepsins, which have also been
shown to be involved in lysosomal a-syn degradation (CTSB,
CTSL) (McGlinchey and Lee, 2015; McGlinchey et al., 2019), are
able to compensate for CTSD deficiencies.
The role of the more active CTSD A239V mutant seems
-on first glance- difficult to explain. However, a recent study
by McGlinchey et al. (2019) showed that C-terminal a-syn
truncations are linked to the enzymatic activity of lysosomal
cathepsins. Importantly, these C-terminally truncated a-syn
forms have been shown to promote aggregation and fibril
formation (Crowther et al., 1998; Hoyer et al., 2004; Levitan et al.,
2011; van der Wateren et al., 2018). In this regard, CSTD has also
been shown to generate C-terminally truncated a-syn variants
(McGlinchey and Lee, 2015). This might explain why this more
active CTSD variant potentially drives a-syn aggregation and
disease pathology. In a follow-up study, this needs to be further
validated by in vitro studies analyzing the cleavage fragments of
a-syn after incubation with the disease-associated CTSD variant.
Moreover, it is also possible that other concomitant genomic
variants represent the primary cause of disease, and that CTSD
mutations are “only” supporting, but not the cause of disease
pathology. This might also be the case for PD patients carrying
the CTSD A239V mutation. Here, follow-up studies are needed to
examine the patients for further genetic variations. For instance,
some AD patients carrying the CSTD A58V variant were also
affected by a mutation within Presenilin 1, which is known
to be associated with early onset AD (Ehling et al., 2013). To
analyze the effect of each individual CTSD point mutation in
disease, analyses of CTSD homeostasis within patient material
(e.g., fibroblasts) should be performed in future studies.
Summarizing, our study sheds light into the structure and
regulation of enzymatic CTSD function as well as a-syn
degradation. This better understanding might enable us in the
future to design treatment strategies targeting CTSD function in
order to reduce abnormal protein aggregation in PD and other
neurodegenerative disorders.
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Supplementary Figure 1 | Generating CTSD deficient cell lines (SH-SY5Y and
H4). (A) A CRISPR/Cas9 RNP (Ribonucleoprotein) approach by using three guide
RNA (gRNA, green arrows and sequence) targeting the CTSD gene at exon 2 was
used. Sanger sequencing analysis from CTSD wt (same sequence for SH-SY5Y
and H4 cells), SH-SY5Y CTSD KO clone 10 (Cl. 10) and H4 CTSD KO clone 2 (Cl.
2) is shown by the corresponding chromatogram of the CTSD exon 2 gene.
RNP-mediated editing resulted in a deletion of 91bp for exon 2 in SH-SY5Y cells
(Cl.10) and a deletion of 106 bp for exon 2 in H4 cells (Cl. 2). (B) Representative
immunoblot of different cell systems comparing endogenous CTSD levels. (C)
Confocal microscopy images of CTSD (green) and lysosomal marker [LAMP2
(red)] in SH-SY5Y cells deficient for CTSD (CTSD KO), CTSD KO reconstituted
with CTSD wt and wt cells exhibiting endogenous CTSD. Analysis of CTSD signal
intensity indicates non-significant (n.s.) higher CTSD level after overexpression in
SH-SY5Y cells in comparison to endogenous CTSD level within SH-SY5Y wt cells
(n = 15 cells). Scale bar: 20 µm. Statistical analyses were performed by using a
one-way ANOVA followed by a Tukey’s multiple comparison test.
Supplementary Figure 2 | Cellular localization of AD-/NCL-associated CTSD
variants in SH-SY5Y CTSD KO cells. Representative confocal microscopy images
of immunofluorescence stainings of CTSD variants overexpressed in SH-SY5Y
CTSD KO cells. Cells were stained for CTSD (green), the lysosomal marker
LAMP2 (red) and DAPI as nuclear stain (blue). Yellow staining indicates lysosomal
localization of CTSD variant. Scale bar: 20 µm.
Supplementary Figure 3 | Analyses of confocal images for CTSD localization,
lysosomal vesicle number and vesicle size. (A) Analysis of intracellular
co-localization of AD-/NCL-associated CTSD variants in SH-SY5Y cells deficient
for CTSD (CTSD KO). The Pearson’s correlation coefficient was used to determine
the co-localization of AD-/NCL-CTSD mutants with lysosomal marker LAMP2
(n = 11–15, derived from cell from three independent experiments). (B)
Quantification of LAMP2-positive vesicle number per cell (n = 11–19, derived from
three independent experiments). (C) Analyses of average LAMP2-positive vesicle
size per cell (n = 12–19, derived from three independent experiments). All
statistical analyses were performed by using a one-way ANOVA followed by a
Tukey’s multiple comparison test. ∗p < 0.05, ∗∗∗p < 0.0001, ∗∗∗∗p < 0.0001,
n.s., not significant in comparison to the wt.
Supplementary Figure 4 | Cellular localization of PD-associated CTSD variants
in SH-SY5Y CTSD KO cells. Representative confocal microscopy images of
immunofluorescence stainings of PD-CTSD variants, overexpressed in SH-SY5Y
cells deficient for CTSD (CTSD KO). Cells were stained for CTSD (green), the
lysosomal marker LAMP2 (red), and DAPI as nuclear stain (blue). Yellow staining
indicates lysosomal localization of CTSD variant. Scale bar: 20 µm.
Supplementary Figure 5 | Analyses of confocal images for CTSD localization,
lysosomal vesicle number, and size as well as maturation of PD-associated CTSD
variants. (A) Analysis of intracellular co-localization of PD-associated CTSD
variants in SH-SY5Y cells deficient for CTSD (CTSD KO). The Pearson’s
correlation coefficient was used to determine the co-localization of PD-CTSD
mutants with lysosomal marker LAMP2 (total n = 11–15 in three independent
experiments). (B) Quantification of LAMP2-positive vesicle number per cell
(n = 11–19, derived from cells from three independent experiments). (C) Analyses
of average LAMP2-positive vesicle size per cell (n = 12–19, derived from three
independent experiments). (D,E) Analysis of protein maturation of PD-CTSD
mutants: ratio of mature CTSD divided by immature CTSD level in SH-SY5Y CTSD
KO cells (D) and H4 CTSD KO cells (E) both normalized to CTSD wt (n = 4–8). All
statistical analyses were performed by using a one-way ANOVA followed by a
Tukey’s multiple comparison test. ∗∗p < 0.01, ∗∗∗∗p < 0.0001.
Supplementary Figure 6 | a-Syn western blot and level after lysosomal inhibition.
(A) Whole immunoblot of Figure 4A exhibiting no a-syn bands at higher molecular
weight (a-syn antibody: Syn-1). (B) Representative immunoblot of SH-SY5Y CTSD
KO cells transfected with CTSD wt co-expressing a-syn. Cells were treated with
lysosomal inhibitor bafilomycin A1 (BafA1) or cathepsin D inhibitor pepstatin A
(PepA), resulting in increased a-syn level (a-syn antibody: Syn-1). Analysis of a-syn
signal after normalization to loading control indicating a significant increase of
a-syn level after treatment of cells with BafA1 and PepA. Statistical analysis was
performed using a one-way ANOVA followed by a multiple comparison test.
Significances were tested against CTSD mock (∗p < 0.05, ∗∗p < 0.01).
Supplementary Figure 7 | Molecular dynamics simulation (MDS) of the A239V
variant of CTSD. (A) Original crystal structure of CTSD (PDB-ID: 4OBZ) bound to
the 2S4 inhibitor. The light chain is displayed in blue, the heavy chain in gray. Active
site residues are shown in spacefill red with 2S4 in orange (ball and stick). Alanine
239 is shown in cyan (ball and stick). (B) As a start conformation for MDS, the 2S4
inhibitor was removed to allow conversion of the structure into an unbound state.
The single amino acid exchange was introduced using UCSF Chimera (swapaa).
Coloring as in (A). (C) Superimposed image of the start conformation (coloring as
in A) and the three end conformations post-MDS (green) for CTSD wt. (D)
Superimposed image of the start conformation (coloring as in A) and the three end
conformations post-MDS (orange) for A239V-CTSD. (E) Superimposed image of
the three end-conformations post-MDS for CTSD wt (green) and CTSD A239V
(orange). The insert shows the loop carrying the A239V variant (filled black arrow)
and the loop formed by amino acids 75–77 located within the light chain (empty
black arrow). (F) As in (E), but with the structures turned by 90◦ around the
y-axis.
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